20 / 38
Updated Guideline Recommendations
•
Consider germline testing in those with metastatic, regional, “very high–risk,”
and “high-risk” localized prostate cancer
•
BRCA1
,
BRCA2
,
ATM
,
PALB2
, and
FANCA
•
Consider somatic testing for homologous recombination deficiency,
microsatellite instability, and mismatch repair deficiency
1. Fizazi K, et al. N Engl J Med. 2017;377:352-360. 2. James ND, et al. N Engl J Med. 2017;377:338-351.